ORYZON Announces Voting Results of its 2024 Annual General Meeting of Shareholders

• All resolutions were approved

• Approval of an additional resolution to increase capital up to 100 million euros

• 42.6867% of issued shares represented

MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) — Oryzon Genomics, SA (ISIN: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies for diseases with high unmet medical need, announced the results of the vote of its Annual General Meeting of Shareholders held today in Madrid. A total of 27,110,751 of the issued and outstanding common shares of the Company (representing 42.6867% of the capital stock) were represented either in person or by proxy at the meeting.

The Company’s shareholders approved all of the resolutions listed below, as proposed by the Board of Directors at the Company’s Annual General Meeting, with favorable votes ranging from 96% to 79%.

• The annual report and financial statements for the year 2023

• Appropriation of loss

• Discharge to the members of the Board of Directors

• Election of a new audit firm for the years 2024-2026 (KPMG)

• Customary delegations to formalize and legalize resolutions

• Remuneration of members of the Board of Directors for the 2023 financial year

• A Capital increase, by way of cash contributions and excluding preferential subscription rights, up to a limit of 100 million euros and delegation to the Board of Directors of the power to set the date, the issue price (or the methods of its determination) and other conditions of issue in accordance with the provisions of Article 505 of the Spanish Companies Act.

Full details of the proposed resolutions which were adopted in full and the results of the independent votes will be available on the Company’s webpage.

About Oryzón
Founded in 2000 in Barcelona, ​​Spain, Oryzon (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. The Oryzon team is comprised of highly skilled pharmaceutical industry professionals located in Barcelona, ​​Boston and San Diego. Oryzon has an advanced clinical pipeline with two LSD1 inhibitors, vafidemstat in the CNS and iadademstat in oncology, in several phase II clinical trials. The company has other assets in the pipeline directed against other epigenetic targets like HDAC-6, where ORY-4001 has been nominated as a clinical candidate for the treatment of certain neurological disorders such as CMT and ALS. Additionally, Oryzon has a robust platform for biomarker identification and target validation for various malignant and neurological diseases. For more information, visit www.oryzon.com

The story continues

FORWARD-LOOKING STATEMENTS
This communication contains or may contain forward-looking information and statements regarding Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations regarding future operations, capital expenditures , synergies, products and services, as well as statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and other similar expressions. Although Oryzon believes that the expectations reflected in these forward-looking statements are reasonable, investors and holders of Oryzon stock are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon, which could cause actual results and developments to differ materially from those expressed, implied or projected by the forward-looking information and statements. These risks and uncertainties include those discussed or identified in documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are publicly available. Forward-looking statements are not guarantees of future performance and have not been reviewed by Oryzon’s auditors. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any person acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon as of the date hereof. Except as required by applicable law, Oryzon undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell any securities in the United States or any other jurisdiction. Oryzon securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon securities in the United States will be made by means of a prospectus which may be obtained from Oryzon or the selling security holder, as applicable, and which will contain detailed information about Oryzon and management , as well as financial statements.